查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年奈米醫學市場預測：按產品類型、適應症、應用和地區分類的全球分析
市場調查報告書
商品編碼
1383450

2030 年奈米醫學市場預測：按產品類型、適應症、應用和地區分類的全球分析

Nanomedicine Market Forecasts to 2030 - Global Analysis By Product Type (Nano Molecules, Nanoshells, Nanotubes, Nanodevices, and Nanoparticles), Modality, Indication, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球奈米藥物市場規模將達2.359億美元，預計2030年將達到4.96億美元，預測期內年複合成長率為11.2%。

市面上有大量用於特定藥物應用的奈米級材料，包括奈米顆粒、奈米載體和奈米管。奈米醫學用於許多醫療應用，包括藥物傳輸、影像、診斷、再生醫學、癌症治療和標靶治療。尤其是奈米顆粒，可望將藥物輸送到體內的精確位置、減少副作用並提高治療效率。

根據2021年7月發表的題為「醫學和癌症奈米材料開發的最新進展」的研究論文，工程奈米材料和奈米平台正在開發中。

人們對標靶藥物輸送的興趣日益濃厚

標靶藥物輸送使藥物化合物（例如化療）能夠精確地輸送到特定的疾病部位，例如癌細胞。透過這樣做，我們可以提供更有效的藥物來治療患者，同時降低健康組織的風險。患者通常會受益於更好的治療結果和更少的副作用。由於藥物集中給藥到所需位置，標靶給藥可以用較低的藥物劑量達到所需的治療效果。這不僅可以最大限度地降低治療成本，還可以減少副作用的機會。標靶藥物傳遞可以提高患者對治療的依從性，減少副作用並提高治療效果，從而改善患者的整體預後。

安全問題

由於安全問題，患者可能對奈米醫學產品缺乏信心並延遲獲得這些治療方法。儘管使用奈米醫學治療方法或參與臨床試驗有潛在的好處，但患者可能不願意這樣做。出於安全考慮，包括醫生和醫院在內的醫療保健提供者可能對提案或使用奈米醫學治療猶豫不決。因此，這些治療方法的臨床推廣可能會被推遲，可能會阻礙市場成長。

奈米科技的進步

奈米技術的不斷突破正在催生具有客製化特性的新型奈米材料。這些材料可以設計成具有特定的性能，如尺寸、形狀、表面化學和生物相容性，使其成為各種醫療應用的理想選擇。奈米技術已經能夠建構先進的藥物傳輸系統，包括脂質體、膠束和奈米顆粒。此外，這些系統可用於以受控和有針對性的方式封裝和釋放藥物，從而提高治療效果並減少副作用。

嚴格的法規要求

由於嚴格的法規限制和冗長的核准程序，將奈米醫學產品推向市場可能會大大延遲。延誤可能會阻礙患者獲得可能挽救生命和改善生命的藥物。對於奈米醫學領域的小型和新成立的公司來說，滿足市場進入的法律和財務先決條件可能特別困難。這些公司可能承受著不成比例的法規障礙，這也限制了它們的競爭能力。法規核准不透明且耗時，這可能會阻止公司和研究人員投資奈米醫學研究。這會抑制產業的創新。

COVID-19 的影響

大流行的緊迫性刺激了奈米醫學領域的研究和開發。奈米技術極大地促進了診斷測試、抗病毒藥物傳輸系統和疫苗接種平台的發展。這項快速行動展示瞭如何利用奈米醫學來應對新出現的衛生緊急情況。 COVID-19 疫苗是使用涉及脂質奈米粒子的奈米醫學技術開發和交付的。各種 COVID-19 疫苗中使用的信使 RNA (mRNA) 被封裝在這些脂質奈米粒子中，確保穩定性和細胞的有效吸收。

奈米殼細分市場預計將在預測期內成為最大的細分市場

透過調整金屬殼的尺寸和成分，奈米殼可以被設計為散射和吸收特定波長的光，這被認為可以為奈米殼片段提供有利的生長。這種特性被用於一種稱為「光熱治療」的方法。這種方法選擇性地在癌細胞內積聚奈米殼，奈米殼響應近紅外線光而產生熱量，對細胞造成局部熱損傷。這種方法提供了一種侵入性較小的去除癌細胞的方法。此外，奈米殼也用於醫學成像。奈米殼在光學同調斷層掃瞄和光聲成像等成像模式中用作造影顯影劑，從而推動了市場的發展。

診斷影像預計在預測期內具有最高的年複合成長率

在奈米醫學領域，診斷成像至關重要，因為它提供了有關身體內部結構和活動的非侵入性且極其詳細的視覺資訊。診斷成像受益於奈米技術的應用，提高了靈敏度、準確性以及針對特定疾病表現的能力。奈米技術的進步有利於分子成像技術，例如單光子發射電腦斷層掃描（SPECT）和正子斷層掃描（PET）。

比最大的地區

北美正在經歷致命疾病數量的增加、奈米醫學市場的蓬勃發展、最先進的醫療設施和合格醫務人員的可用性、涉及知名人士的研發計劃的增加以及政府支出的增加在醫療保健領域，預計將在預測期內佔據最大的市場佔有率。此外，該國正在進行大量基於奈米技術的藥物和診斷的研發計劃，這可能會促進市場擴張。例如，2020 年 1 月，史丹佛大學的科學家開發了一種塗有奈米顆粒的藥物，可以透過減少小鼠動脈中形成的斑塊數量來預防小鼠動脈粥狀硬化的發展，而且沒有任何副作用。我們開發了一種新藥。

複合年複合成長率最高的地區：

由於公眾對奈米科學和奈米技術相關共識會議的興趣不斷增加，以及對奈米醫學的認知不斷提高，預計亞太地區在預測期內將呈現最高的年複合成長率。例如，第九屆國際奈米科學與技術會議（ChinaNANO 2022）於2022年8月在中國北京舉行。會議的目的是共用科學發現、特定產業的進展、技術創新以及新的機會和挑戰。此外，部門的開拓、新興市場改革的興起、奈米醫學領域的技術進步以及醫療基礎設施的改善是中國和日本預計在亞太市場實現高年複合成長率的主要原因。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球奈米醫學市場：依產品類型

  • 奈米分子
  • 奈米殼
  • 奈米管
  • 奈米裝置
  • 奈米顆粒
    • 金屬和金屬氧化物奈米顆粒
    • 樹枝狀聚合物
    • 水凝膠奈米粒子
    • 無機奈米粒子
    • 脂質體
    • 聚合物和聚合物藥物綴合物

第6章 全球奈米醫學市場：依適應症分類

  • 感染疾病
  • 心血管疾病
  • 腫瘤性疾病
  • 整形外科疾病
  • 神經系統疾病
  • 泌尿系統疾病
  • 眼科疾病
  • 其他適應症

第7章 全球奈米醫學市場：依應用分類

  • 診斷影像
  • 再生醫學
  • 藥物輸送
  • 疫苗
  • 植入
  • 其他用途

第8章 全球奈米醫學市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Abbott
  • Sanofi SA
  • Pfizer Inc.
  • GE Healthcare
  • CombiMatrix Corporation
  • Johnson & Johnson Services Inc.
  • Luminex Corporation
  • Merck & Company Inc.
  • Nanosphere Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • DiaSorin SpA
  • Invitae Corporation
  • Mallinckrodt plc
  • Leadient BioSciences Inc.
  • Teva Pharmaceuticals Ltd.
  • Nanospectra Biosciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Ablynx
  • CytImmune Sciences
Product Code: SMRC24298

According to Stratistics MRC, the Global Nanomedicine Market is accounted for $235.9 million in 2023 and is expected to reach $496.0 million by 2030 growing at a CAGR of 11.2% during the forecast period. A vast array of nanoscale materials, including nanoparticles, nanocarriers, and nanotubes, that are intended for particular medicinal uses are available on the market. Numerous medical applications, such as medication delivery, imaging, diagnostics, regenerative medicine, cancer therapy, and targeted therapy, have made use of nanomedicine. Particularly nanoparticles have demonstrated promise in delivering medications to precise parts of the body, lowering side effects, and enhancing therapeutic efficiency.

According to a research article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer", published in July 2021, a wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and compositions has been developed for various biomedical applications.

Market Dynamics:

Driver:

Growing interest on targeted drug delivery

With targeted medication delivery, medicinal compounds (such chemotherapy treatments) may be precisely delivered to certain disease locations, like cancer cells. By doing this, medications become more effective in treating patients while posing less of a risk to healthy tissues. Patients frequently benefit from this in terms of better treatment results and fewer side effects. Because the medication is concentrated at the intended place, targeted drug delivery can produce the intended therapeutic effect at lower drug dosages. This minimizes the expense of therapy as well as the chance of adverse consequences. Targeted medication delivery can improve patient compliance with therapy, which improves overall patient outcomes, by reducing side effects and improving treatment effectiveness.

Restraint:

Safety concerns

Patients may get less confident in nanomedicine products due to safety concerns, which may cause them to delay utilizing these treatments. Even if using nanomedicine therapies or taking part in clinical trials may have potential advantages, patients may be reluctant to do so. Because of safety concerns, healthcare providers including doctors and hospitals may be hesitant to propose or use nanomedicine therapy. As a result, these therapies may be adopted into clinical practice more slowly thus hampering the market growth.

Opportunity:

Increasing advancements in nanotechnology

Novel nanomaterials with customized characteristics have been created as a result of on-going breakthroughs in nanotechnology. These materials are ideal for a range of medical applications because they may be engineered to have certain properties including size, shape, surface chemistry, and biocompatibility. The creation of sophisticated medication delivery systems including liposomes, micelles, and nanoparticles has been made possible by nanotechnology. Moreover, the efficacy of therapies can be increased and adverse effects can be decreased by using these systems to encapsulate and release medications in a controlled and targeted way.

Threat:

Stringent regulatory requirements

The release of goods utilizing nanomedicines into the market might be seriously delayed by onerous regulatory restrictions and protracted approval procedures. Access for patients to potentially life-saving or life-improving medicines may be hampered by delays. It may be especially difficult for small and newly established businesses in the field of nanomedicine to fulfil the legal and financial prerequisites for entering the market. These businesses may be disproportionately burdened by regulatory obstacles, which also restrict their capacity to compete. Because regulatory approval is unclear and takes time, companies and researchers may be deterred from investing in nanomedicine research. This may inhibit industry innovation.

COVID-19 Impact

The pandemic's urgency spurred study and development in the field of nanomedicine. The development of diagnostic testing, antiviral medication delivery systems, and vaccination platforms were significantly aided by nanotechnology. This prompt action showed how nanomedicine may be used to meet new health emergencies. COVID-19 vaccines were developed and delivered using nanomedicine technology, including lipid nanoparticles. The messenger RNA (mRNA) utilized in various COVID-19 vaccines is encapsulated in these lipid nanoparticles, which guarantees their stability and effective uptake by cells.

The nanoshells segment is expected to be the largest during the forecast period

The nanoshells segment is estimated to have a lucrative growth, as these may be engineered to scatter and absorb light at particular wavelengths by adjusting the metallic shell's size and composition. This characteristic is utilized in a method known as "photothermal therapy." This approach involves the selective accumulation of nanoshells within cancer cells, which heat up in response to near-infrared light and inflict localized thermal damage on the cells. This method provides a less intrusive means of eliminating cancer cells. Moreover, nanoshells have been used to medical imaging. They can be used as contrast agents in imaging modalities such as optical coherence tomography and photoacoustic imaging which boosts the market.

The diagnostic imaging segment is expected to have the highest CAGR during the forecast period

The diagnostic imaging segment is anticipated to witness the highest CAGR growth during the forecast period, as in the field of nanomedicine, diagnostic imaging is essential because it offers non-invasive, incredibly detailed visual information on the interior structures and activities of the body. Diagnostic imaging has benefited from the application of nanotechnology, which has increased sensitivity, accuracy, and the capacity to target certain disease signs. Advances in nanotechnology have been beneficial for molecular imaging techniques like single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing an increase in the number of deadly illnesses, a spike in the market for nanomedicines, the availability of cutting-edge medical facilities staffed by qualified medical personnel, an increase in the number of R&D projects involving prominent figures, and an increase in government spending in the healthcare sector. Additionally, the nation is conducting a number of R&D projects on medications and diagnostics based on nanotechnology, which might propel market expansion. For example, in January 2020, scientists at Stanford University created a medication coated with nanoparticles that prevents mice from developing atherosclerosis by lowering the amount of plaque that accumulates in their arteries without having any negative side effects.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to public's growing interest in consensus conferences related to nanoscience and nanotechnology as well as the growing awareness of nanomedicine. For example, ChinaNANO 2022, the 9th International Conference on Nanoscience and Technology, was held in Beijing, China in August 2022. The purpose of the conference is to share scientific discoveries, advances in certain industries, technological innovations, and novel opportunities and challenges. Furthermore, the development of the R&D sector, the rise in healthcare reforms, the advancement of technology in the field of nanomedicines, and improvements in healthcare infrastructure are the main reasons why China and Japan are predicted to grow at a high compound annual growth rate (CAGR) in the Asia-Pacific market.

Key players in the market

Some of the key players profiled in the Nanomedicine Market include: Abbott, Sanofi SA, Pfizer Inc., GE Healthcare, CombiMatrix Corporation, Johnson & Johnson Services Inc., Luminex Corporation, Merck & Company Inc., Nanosphere Inc. , Celgene Corporation, Bristol-Myers Squibb Company, DiaSo, Invitae Corporation, Mallinckrodt plc, Leadient BioSciences Inc., Teva Pharmaceuticals Ltd., Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Ablynx and CytImmune Sciences

Key Developments:

In November 2023, Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

In October 2023, Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment. Collaboration supports Sanofi's immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Product Types Covered:

  • Nano Molecules
  • Nanoshells
  • Nanotubes
  • Nanodevices
  • Nanoparticles

Indications Covered:

  • Infectious Diseases
  • Cardiovascular Diseases
  • Oncological Diseases
  • Orthopedic Diseases
  • Neurological Disorders
  • Urological Disorders
  • Ophthalmological Diseases
  • Other Indications

Applications Covered:

  • Diagnostic Imaging
  • Regenerative Medicine
  • Drug Delivery
  • Vaccines
  • Implants
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nano Molecules
  • 5.3 Nanoshells
  • 5.4 Nanotubes
  • 5.5 Nanodevices
  • 5.6 Nanoparticles
    • 5.6.1 Metal & Metal Oxide Nanoparticles
    • 5.6.2 Dendrimers
    • 5.6.3 Hydrogel Nanoparticles
    • 5.6.4 Inorganic nanoparticles
    • 5.6.5 Liposomes
    • 5.6.6 Polymer and Polymer Drug Conjugates

6 Global Nanomedicine Market, By Indication

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cardiovascular Diseases
  • 6.4 Oncological Diseases
  • 6.5 Orthopedic Diseases
  • 6.6 Neurological Disorders
  • 6.7 Urological Disorders
  • 6.8 Ophthalmological Diseases
  • 6.9 Other Indications

7 Global Nanomedicine Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnostic Imaging
  • 7.3 Regenerative Medicine
  • 7.4 Drug Delivery
  • 7.5 Vaccines
  • 7.6 Implants
  • 7.7 Other Applications

8 Global Nanomedicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott
  • 10.2 Sanofi SA
  • 10.3 Pfizer Inc.
  • 10.4 GE Healthcare
  • 10.5 CombiMatrix Corporation
  • 10.6 Johnson & Johnson Services Inc.
  • 10.7 Luminex Corporation
  • 10.8 Merck & Company Inc.
  • 10.9 Nanosphere Inc.
  • 10.10 Celgene Corporation
  • 10.11 Bristol-Myers Squibb Company
  • 10.12 DiaSorin S.p.A.
  • 10.13 Invitae Corporation
  • 10.14 Mallinckrodt plc
  • 10.15 Leadient BioSciences Inc.
  • 10.16 Teva Pharmaceuticals Ltd.
  • 10.17 Nanospectra Biosciences, Inc.
  • 10.18 Arrowhead Pharmaceuticals, Inc.
  • 10.19 Ablynx
  • 10.20 CytImmune Sciences

List of Tables

  • Table 1 Global Nanomedicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine Market Outlook, By Nano Molecules (2021-2030) ($MN)
  • Table 4 Global Nanomedicine Market Outlook, By Nanoshells (2021-2030) ($MN)
  • Table 5 Global Nanomedicine Market Outlook, By Nanotubes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine Market Outlook, By Nanodevices (2021-2030) ($MN)
  • Table 7 Global Nanomedicine Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 8 Global Nanomedicine Market Outlook, By Metal & Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 9 Global Nanomedicine Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 10 Global Nanomedicine Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 11 Global Nanomedicine Market Outlook, By Inorganic nanoparticles (2021-2030) ($MN)
  • Table 12 Global Nanomedicine Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 13 Global Nanomedicine Market Outlook, By Polymer and Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 14 Global Nanomedicine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 15 Global Nanomedicine Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 16 Global Nanomedicine Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 17 Global Nanomedicine Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 18 Global Nanomedicine Market Outlook, By Orthopedic Diseases (2021-2030) ($MN)
  • Table 19 Global Nanomedicine Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 20 Global Nanomedicine Market Outlook, By Urological Disorders (2021-2030) ($MN)
  • Table 21 Global Nanomedicine Market Outlook, By Ophthalmological Diseases (2021-2030) ($MN)
  • Table 22 Global Nanomedicine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 23 Global Nanomedicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Nanomedicine Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 25 Global Nanomedicine Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 26 Global Nanomedicine Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 27 Global Nanomedicine Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 28 Global Nanomedicine Market Outlook, By Implants (2021-2030) ($MN)
  • Table 29 Global Nanomedicine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.